Aytu Biopharma, Inc.
AYTU
$2.13
-$0.05-2.29%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -6.51% | -16.21% | 3.71% | 31.57% | -13.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.51% | -16.21% | 3.71% | 31.57% | -13.48% |
| Cost of Revenue | 1.95% | 2.46% | 37.84% | 54.09% | 31.12% |
| Gross Profit | -10.77% | -23.35% | -7.22% | 23.60% | -26.14% |
| SG&A Expenses | 13.86% | -4.99% | -10.30% | -8.64% | -2.96% |
| Depreciation & Amortization | -42.89% | -51.79% | 0.00% | 0.00% | 0.33% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.23% | -7.94% | -3.07% | 4.25% | 6.39% |
| Operating Income | -421.16% | -930.14% | 277.29% | 278.94% | -112.02% |
| Income Before Tax | -2,870.68% | 31.17% | -666.38% | 316.07% | -72.69% |
| Income Tax Expenses | -- | -- | -48.04% | -123.42% | -136.28% |
| Earnings from Continuing Operations | -1,691.58% | 79.78% | -488.51% | 272.20% | 7.43% |
| Earnings from Discontinued Operations | -- | -- | 105.00% | 109.02% | 114.66% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,443.15% | 33.31% | -329.24% | 238.34% | 458.18% |
| EBIT | -421.16% | -930.14% | 277.29% | 278.94% | -112.02% |
| EBITDA | -218.71% | -159.01% | 61.57% | 1,976.67% | -81.49% |
| EPS Basic | -920.70% | -14.33% | -255.16% | 224.80% | 422.06% |
| Normalized Basic EPS | -480.54% | -44.64% | -30,161.76% | 326.16% | 9.27% |
| EPS Diluted | -301.60% | 49.97% | -255.16% | 139.60% | -523.75% |
| Normalized Diluted EPS | -626.86% | -59.73% | -30,161.76% | 269.07% | -21.07% |
| Average Basic Shares Outstanding | 63.67% | 55.59% | 20.85% | 10.86% | 11.14% |
| Average Diluted Shares Outstanding | 18.28% | 114.04% | 20.85% | 48.27% | 53.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |